LYN

Overview

LYN encodes a SRC-family non-receptor tyrosine kinase involved in signal transduction downstream of growth factor receptors and immune receptors. In oral squamous cell carcinoma (OSCC) and head and neck squamous cell carcinoma (HNSCC), LYN is altered as part of a broader pattern of SRC-family kinase (SFK) copy gains that collectively affect approximately 29% of tumors.

Alterations observed in the corpus

  • SRC-family kinase (SFK) collectively altered in 29% (10/35) of OSCC tumors alongside SRC and YES1; LYN copy gain with high expression identified as a candidate therapeutic target in HNSCC PMID:23619168

Cancer types (linked)

  • OSCC (Oral Squamous Cell Carcinoma): copy gain with expression correlation; part of SRC-family kinase alterations present in 29% of HNSCC tumors PMID:23619168

Co-occurrence and mutual exclusivity

  • Co-altered with SRC and YES1 in the SRC-family kinase category in HNSCC; part of broader mitogenic signaling landscape including EGFR, PIK3CA, AKT1, HRAS, and BRAF alterations PMID:23619168

Therapeutic relevance

  • SRC-family kinases are established cancer therapeutic targets; 80% of OSCC tumors in this cohort harbored at least one alteration in an established therapeutic target gene; SFK inhibitors (dasatinib and others) represent candidate agents PMID:23619168

Open questions

  • Relative contribution of LYN versus other SRC-family kinases (SRC, YES1) to HNSCC pathogenesis is not individually quantified; combinatorial alteration patterns are not fully characterized PMID:23619168

Sources

This page was processed by crosslinker on 2026-05-09.